AAAAAA
Results:
1-15
|
Results: 15
Authors:
Sievers, EL
Citation: El. Sievers, Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukaemia in first relapse, EXPERT OP B, 1(5), 2001, pp. 893-901
Authors:
Sievers, EL
Linenberger, M
Citation: El. Sievers et M. Linenberger, Mylotarg: antibody-targeted chemotherapy comes of age, CURR OPIN O, 13(6), 2001, pp. 522-527
Authors:
Perentesis, JP
Sievers, EL
Citation: Jp. Perentesis et El. Sievers, Targeted therapies for high-risk acute myeloid leukemia, HEMAT ONCOL, 15(4), 2001, pp. 677
Authors:
Soignet, SL
Frankel, SR
Douer, D
Tallman, MS
Kantarjian, H
Calleja, E
Stone, RM
Kalaycio, M
Scheinberg, DA
Steinherz, P
Sievers, EL
Coutre, S
Dahlberg, S
Ellison, R
Warrell, RP
Citation: Sl. Soignet et al., United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia, J CL ONCOL, 19(18), 2001, pp. 3852-3860
Authors:
Sievers, EL
Larson, RA
Stadtmauer, EA
Estey, E
Lowenberg, B
Dombret, H
Karanes, C
Theobald, M
Bennett, JM
Sherman, ML
Berger, MS
Eten, CB
Loken, MR
van Dongen, JJM
Bernstein, ID
Appelbaum, FR
Citation: El. Sievers et al., Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse, J CL ONCOL, 19(13), 2001, pp. 3244-3254
Authors:
Linenberger, ML
Hong, T
Flowers, D
Sievers, EL
Gooley, TA
Bennett, JM
Berger, MS
Leopold, LH
Appelbaum, FR
Bernstein, ID
Citation: Ml. Linenberger et al., Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin, BLOOD, 98(4), 2001, pp. 988-994
Authors:
Rocha, V
Cornish, J
Sievers, EL
Filipovich, A
Locatelli, F
Peters, C
Remberger, M
Michel, G
Arcese, W
Dallorso, S
Tiedemann, K
Busca, A
Chan, KW
Kato, S
Ortega, J
Vowels, M
Zander, A
Souillet, G
Oakill, A
Woolfrey, A
Pay, AL
Green, A
Garnier, F
Ionescu, I
Wernet, P
Sirchia, G
Rubinstein, P
Chevret, S
Gluckman, E
Citation: V. Rocha et al., Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia, BLOOD, 97(10), 2001, pp. 2962-2971
Authors:
Thorson, JS
Sievers, EL
Ahlert, J
Shepard, E
Whitwam, RE
Onwueme, KC
Ruppen, M
Citation: Js. Thorson et al., Understanding and exploiting nature's chemical arsenal: The past, present and future of calicheamicin research, CUR PHARM D, 6(18), 2000, pp. 1841-1879
Authors:
Frankel, AE
Sievers, EL
Scheinberg, DA
Citation: Ae. Frankel et al., Cell surface receptor-targeted therapy of acute myeloid leukemia: A review, CANC BIO R, 15(5), 2000, pp. 459-476
Authors:
Sievers, EL
Lange, BJ
Sondel, PM
Krailo, MD
Gan, J
Tjoa, T
Mares, WL
Feig, SA
Citation: El. Sievers et al., Children's Cancer Group trials of interleukin-2 therapy to prevent relapseof acute myelogenous leukemia, CA J SCI AM, 6, 2000, pp. S39-S44
Authors:
Sievers, EL
Radich, JP
Citation: El. Sievers et Jp. Radich, Detection of minimal residual disease in acute leukemia, CURR OPIN H, 7(4), 2000, pp. 212-216
Authors:
Sievers, EL
Citation: El. Sievers, Clinical studies of new "biologic" approaches to therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates, CURR OPIN O, 12(1), 2000, pp. 30-35
Authors:
Sievers, EL
Citation: El. Sievers, Targeted therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates, CANC CHEMOT, 46, 2000, pp. S18-S22
Authors:
Cooper, LJN
Shannon, KM
Loken, MR
Weaver, M
Stephens, K
Sievers, EL
Citation: Ljn. Cooper et al., Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell, BLOOD, 96(6), 2000, pp. 2310-2313
Authors:
Sievers, EL
Appelbaum, FR
Spielberger, RT
Forman, SJ
Flowers, D
Smith, FO
Shannon-Dorcy, K
Berger, MS
Bernstein, ID
Citation: El. Sievers et al., Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate, BLOOD, 93(11), 1999, pp. 3678-3684
Risultati:
1-15
|